<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>527</serviceExecutionTime><Drug id="59143"><DrugName>clazakizumab</DrugName><DrugNamesKey><Name id="42972763">clazakizumab</Name></DrugNamesKey><DrugSynonyms><Name><Value>ALD-518</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>anti-IL6 monoclonal antibody (rheumatoid arthritis/cancer), Alder Biopharmaceuticals/BMS</Value></Name><Name><Value>anti-IL6 mAb (rheumatoid arthritis/cancer), Alder/Bristol-Myers Squibb</Value></Name><Name><Value>clazakizumab</Value><Types><Type>USAN</Type><Type>PINN</Type></Types></Name><Name><Value>BMS-945429</Value><Types><Type>Research Code</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1014060">Alder Biopharmaceuticals Inc</CompanyOriginator><CompaniesPrimary><Company id="1007640">CSL Behring LLC</Company><Company id="1123559">Vitaeris Inc</Company></CompaniesPrimary><CompaniesSecondary><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="59143" type="Drug"><TargetEntity id="468410" type="siDrug">Clazakizumab</TargetEntity></SourceEntity><SourceEntity id="1007640" type="Company"><TargetEntity id="5000042200" type="organizationId">CSL Behring LLC</TargetEntity></SourceEntity><SourceEntity id="1014060" type="Company"><TargetEntity id="4296032231" type="organizationId">Alder Biopharmaceuticals Inc</TargetEntity></SourceEntity><SourceEntity id="1123559" type="Company"><TargetEntity id="5050921010" type="organizationId">Vitaeris Inc</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="17" type="ciIndication"><TargetEntity id="10002034" type="MEDDRA"></TargetEntity><TargetEntity id="D000740" type="MeSH"></TargetEntity><TargetEntity id="-201701473" type="omicsDisease"></TargetEntity><TargetEntity id="988" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="1781" type="ciIndication"><TargetEntity id="10037162" type="MEDDRA"></TargetEntity><TargetEntity id="D015535" type="MeSH"></TargetEntity><TargetEntity id="-689721545" type="omicsDisease"></TargetEntity><TargetEntity id="724" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="291" type="ciIndication"><TargetEntity id="10039073" type="MEDDRA"></TargetEntity><TargetEntity id="D001172" type="MeSH"></TargetEntity><TargetEntity id="-1391695545" type="omicsDisease"></TargetEntity><TargetEntity id="749" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="2989" type="ciIndication"><TargetEntity id="T86.11" type="ICD10"></TargetEntity><TargetEntity id="10023439" type="MEDDRA"></TargetEntity><TargetEntity id="1136" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="425" type="ciIndication"><TargetEntity id="R64" type="ICD10"></TargetEntity><TargetEntity id="10006895" type="MEDDRA"></TargetEntity><TargetEntity id="D002100" type="MeSH"></TargetEntity><TargetEntity id="-1500634021" type="omicsDisease"></TargetEntity><TargetEntity id="1127" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="616" type="ciIndication"><TargetEntity id="D89.81" type="ICD10"></TargetEntity><TargetEntity id="10018651" type="MEDDRA"></TargetEntity><TargetEntity id="D006086" type="MeSH"></TargetEntity><TargetEntity id="39812" type="ORPHANET"></TargetEntity><TargetEntity id="-1437372564" type="omicsDisease"></TargetEntity><TargetEntity id="1129" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="829" type="ciIndication"><TargetEntity id="10016256" type="MEDDRA"></TargetEntity><TargetEntity id="D005221" type="MeSH"></TargetEntity><TargetEntity id="-961418346" type="omicsDisease"></TargetEntity><TargetEntity id="2620" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="84" type="ciIndication"><TargetEntity id="K50" type="ICD10"></TargetEntity><TargetEntity id="10011401" type="MEDDRA"></TargetEntity><TargetEntity id="D003424" type="MeSH"></TargetEntity><TargetEntity id="-248155260" type="omicsDisease"></TargetEntity><TargetEntity id="395" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="471" type="Action"><TargetEntity id="756" type="Mechanism">IL-6 Receptor Antagonists</TargetEntity><TargetEntity id="3056" type="Mechanism">IL-6 Antagonists</TargetEntity><TargetEntity id="1548" type="Mechanism">Anti-IL-6</TargetEntity></SourceEntity><SourceEntity id="2953" type="Action"><TargetEntity id="775" type="Mechanism">Antiinflammatory Drugs</TargetEntity><TargetEntity id="802" type="Mechanism">Mediator Release Inhibitors</TargetEntity></SourceEntity><SourceEntity id="PTGT-00987" type="ciTarget"><TargetEntity id="56621" type="siTarget">IL-6 receptor</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><IndicationsPrimary><Indication id="2989">Kidney transplant rejection</Indication><Indication id="3878">Organ transplant rejection</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="17">Anemia</Indication><Indication id="1781">Psoriatic arthritis</Indication><Indication id="291">Rheumatoid arthritis</Indication><Indication id="3209">Oral mucositis</Indication><Indication id="425">Cachexia</Indication><Indication id="616">Graft versus host disease</Indication><Indication id="829">Fatigue</Indication><Indication id="84">Crohns disease</Indication></IndicationsSecondary><ActionsPrimary><Action id="471">IL-6 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2953">Anti-inflammatory</Action></ActionsSecondary><Technologies><Technology id="85">Protein recombinant</Technology><Technology id="761">Biological therapeutic</Technology><Technology id="740">Infusion</Technology><Technology id="648">Intravenous formulation</Technology><Technology id="647">Subcutaneous formulation</Technology><Technology id="169">Monoclonal antibody humanized</Technology></Technologies><LastModificationDate>2019-05-24T11:22:35.000Z</LastModificationDate><ChangeDateLast>2019-05-24T00:00:00.000Z</ChangeDateLast><AddedDate>2008-01-11T16:54:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1123559" linkType="Company"&gt;Vitaeris&lt;/ulink&gt;, under license from &lt;ulink linkID="1014060" linkType="Company"&gt;Alder Biopharmaceuticals&lt;/ulink&gt;, and in  collaboration with &lt;ulink linkID="1007640" linkType="Company"&gt;CSL Behring&lt;/ulink&gt; and parent company  &lt;ulink linkID="15563" linkType="Company"&gt;CSL Ltd&lt;/ulink&gt;, is developing  clazakizumab (ALD-518; BMS-945429), a neutralizing humanized mAb against IL-6 produced in the company's Mab X-press yeast culture system, as a potential therapeutic option for solid organ transplant rejection [&lt;ulink linkID="617781" linkType="Reference"&gt;617781&lt;/ulink&gt;], [&lt;ulink linkID="1759657" linkType="Reference"&gt;1759657&lt;/ulink&gt;],  [&lt;ulink linkID="1988123" linkType="Reference"&gt;1988123&lt;/ulink&gt;], [&lt;ulink linkID="1988272" linkType="Reference"&gt;1988272&lt;/ulink&gt;], [&lt;ulink linkID="1987835" linkType="Reference"&gt;1987835&lt;/ulink&gt;]. In May 2019, a phase III trial was  initiated  in kidney transplant recipients with chronic AMR    [&lt;ulink linkID="2155021" linkType="Reference"&gt;2155021&lt;/ulink&gt;]. In January 2018, an investigator-led phase II trial was initiated in kidney transplant recipients with late antibody-mediated rejection (AMR), in collaboration with Vitaeris [&lt;ulink linkID="2049740" linkType="Reference"&gt;2049740&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In June 2011, former licensee &lt;ulink linkID="15065" linkType="Company"&gt;Bristol-Myers Squibb&lt;/ulink&gt; (BMS) initiated a phase IIb RA trial [&lt;ulink linkID="1201269" linkType="Reference"&gt;1201269&lt;/ulink&gt;], [&lt;ulink linkID="1226335" linkType="Reference"&gt;1226335&lt;/ulink&gt;].    In January  2012, BMS initiated a phase II psoriatic arthritis trial  [&lt;ulink linkID="1253802" linkType="Reference"&gt;1253802&lt;/ulink&gt;]. In February 2014, the drug was listed as being in phase II development on BMS pipeline [&lt;ulink linkID="1543464" linkType="Reference"&gt;1543464&lt;/ulink&gt;]. However, in September 2014, BMS terminated its collaboration with Alder. At that time, Alder would continue development of drug for autoimmune/inflammatory diseases [&lt;ulink linkID="1590051" linkType="Reference"&gt;1590051&lt;/ulink&gt;], and in March 2015, Alder only listed the drug as being developed for RA and psoriatic arthritis [&lt;ulink linkID="1642989" linkType="Reference"&gt;1642989&lt;/ulink&gt;]. However, by December 2017, Vitaeris had refocused clazakizumab's development, and it is presumed that development in RA and psoriatic arthritis  had been discontinued since the company only listed solid organ transplant rejection as the solely therapeutic indication pursued by the company [&lt;ulink linkID="1988272" linkType="Reference"&gt;1988272&lt;/ulink&gt;], [&lt;ulink linkID="1988123" linkType="Reference"&gt;1988123&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The drug was previously being developed for other  indications, including cachexia. In  September 2008, Alder initiated a phase II trial in cancer-related anemia, fatigue and cachexia [&lt;ulink linkID="1014302" linkType="Reference"&gt;1014302&lt;/ulink&gt;]; in June 2010, positive results from the phase II study were presented [&lt;ulink linkID="1103193" linkType="Reference"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkID="1104799" linkType="Reference"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkID="1105952" linkType="Reference"&gt;1105952&lt;/ulink&gt;]. in July 2011, a phase II trial in radiotherapy-induced oral mucositis trial was initiated [&lt;ulink linkID="1211333" linkType="Reference"&gt;1211333&lt;/ulink&gt;].     In March 2012, Alder initiated a phase I/II trial in GVHD patients [&lt;ulink linkID="1276771" linkType="Reference"&gt;1276771&lt;/ulink&gt;].  In August 2012, a phase II Crohn's disease trial was initiated [&lt;ulink linkID="1318111" linkType="Reference"&gt;1318111&lt;/ulink&gt;];  however, by June 2013, the trial had been terminated [&lt;ulink linkID="1276534" linkType="Reference"&gt;1276534&lt;/ulink&gt;]. By March 2015, the company had deprioritized its cancer-related development of clazakizumab [&lt;ulink linkID="1642989" linkType="Reference"&gt;1642989&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;In March 2015, Alder stated that patents covering clazakizumab in the US and other regions expire between 2028 and 2031. In the US, clazakizumab is protected by 9 patents specifically directed to the use of clazakizumab alone or in combination to treat or prevent human disease conditions associated with elevated IL-6, which expire  between 2028 and 2030 [&lt;ulink linkID="1642989" linkType="Reference"&gt;1642989&lt;/ulink&gt;], [&lt;ulink linkID="1737217" linkType="Reference"&gt;1737217&lt;/ulink&gt;]. In February 2016, Alder Biopharmaceuticals stated that it held a US patent with granted claims directed to the clazakizumab antibody and compositions containing that antibody, and a US patent with granted claims directed to nucleic acids encoding clazakizumab and its methods of use both of which expire in 2028 [&lt;ulink linkID="1737217" linkType="Reference"&gt;1737217&lt;/ulink&gt;].&lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2017, launch in the transplant setting was anticipated between 2020 and 2023 [&lt;ulink linkID="1987835" linkType="Reference"&gt;1987835&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, filing for  cancer cachexia had been expected in 2011 [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Organ transplant rejection&lt;/subtitle&gt;In December 2018, a randomized, parallel-assignment, double-blind, placebo-controlled, phase III trial (&lt;ulink linkID="360479" linkType="Protocol"&gt;NCT03744910&lt;/ulink&gt;; VKTX01; IMAGINE) was planned to begin in March 2019 to assess the safety and efficacy of clazakizumab for the treatment of chronic active antibody-mediated rejection in patients (expected n = 350) receiving kidney transplants. The primary endpoint was incidence of all cause composite allograft loss. At that time, the trial was expected to complete in July 2027 [&lt;ulink linkID="2106931" linkType="Reference"&gt;2106931&lt;/ulink&gt;]. In May 2019, phase III trial (Eudra 2018-003682-34) was initiated in Hungary, Spain, Canada, Isarel and the US [&lt;ulink linkID="2155021" linkType="Reference"&gt;2155021&lt;/ulink&gt;]. In April 2019, the trial was expected to complete in April 2028  [&lt;ulink linkID="2106931" linkType="Reference"&gt;2106931&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2018, Vitaeris was collaborating on a &lt;ulink linkID="1015721" linkType="Company"&gt;Medical University of Vienna&lt;/ulink&gt;-led, randomized, double-blind, parallel assignment, interventional, phase II trial (&lt;ulink linkID="330314" linkType="Protocol"&gt;NCT03444103&lt;/ulink&gt;; EK1428/2017; 2017-001604-30) to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of clazakizumab in kidney transplant recipients (expected n = 20) with late antibody-mediated rejection (ABMR), that was initiated in Austria and Germany. The primary endpoint was number of adverse events and severe adverse events. At that time, the trial was to complete in June 2020 [&lt;ulink linkID="2049740" linkType="Reference"&gt;2049740&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2017, a clinical study was being initiated in the renal transplant rejection setting to further evaluate the role of IL-6 blockade  for the preservation of renal function and prevention of  renal allograft loss from antibody mediated rejection. At that time, dosing in antibody mediated rejection patients was anticipated to start in 2018 [&lt;ulink linkID="1988123" linkType="Reference"&gt;1988123&lt;/ulink&gt;], [&lt;ulink linkID="1987835" linkType="Reference"&gt;1987835&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Rheumatoid arthritis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;n September 2009, Alder had expected to initiate a phase III study in RA during 2010 [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In February 2014, a phase IIb randomized, multi-center, double-blind, dose-ranging efficacy and safety study (&lt;ulink linkID="166001" linkType="Protocol"&gt;NCT02015520&lt;/ulink&gt;; 	IM133-066, 2013-003780-65) of clazakizumab was initiated in patients (expected n = 140) with moderate to severe active rheumatoid arthritis who have experienced an inadequate response to TNF inhibitors. At that time, the study was expected to complete in August 2018 [&lt;ulink linkID="1571082" linkType="Reference"&gt;1571082&lt;/ulink&gt;]. In June 2014, the estimated primary outcome in the phase IIb follow-on trial was expected in the first half of 2015 [&lt;ulink linkID="1571014" linkType="Reference"&gt;1571014&lt;/ulink&gt;]. In May 2015, data from the follow-on study were reported. The study met the primary endpoint. In the study,  5 and 25 mg groups showed significant efficacy compared to placebo. The drug was well-tolerated. At that time, complete data were expected to be presented at a scientific meeting [&lt;ulink linkID="1656748" linkType="Reference"&gt;1656748&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, BMS initiated a randomized, double-blind, dose-ranging, placebo/active controlled, phase IIb trial (&lt;ulink linkID="78148" linkType="Protocol"&gt;NCT01373151&lt;/ulink&gt;; IM133-001; 2010-023956-99) in the US, Europe, South America, Canada, South Africa and the Far East, including Japan, in patients (expected n = 406) with moderate to severe RA with inadequate response to methotrexate. At that time, trial completion was expected in December 2013  [&lt;ulink linkID="1201269" linkType="Reference"&gt;1201269&lt;/ulink&gt;], [&lt;ulink linkID="1226335" linkType="Reference"&gt;1226335&lt;/ulink&gt;]. In October 2013, data from the study were presented at the 77th ACR/ARHP Annual Meeting in San Diego, CA. The primary endpoint of clazakizumab superiority to placebo in combination with methotrexate at 12 weeks of treatment was met. At that time, 78.0, 71.7 and 66.0% of the patients receiving clazakizumab plus methotrexate, 55.0 and 61.0% of those receiving clazakizumab monotherapy showed an ACR20 response, compared to 39.3% of patients in the placebo arm. Remission rates using clinical criteria (CDAI &amp;lt;/= 2.8) similarly indicated superiority of clazakizumab versus placebo at week 24, with rates of 15.3, 20.0 and 20.0% with 25-, 100- and 200-mg clazakizumab combination with methotrexate, 6.7 and 6.8% with clazakizumab monotherapy, compared with  1.6% with  placebo. The treatment was reasonably well tolerated [&lt;ulink linkID="1492929" linkType="Reference"&gt;1492929&lt;/ulink&gt;], [&lt;ulink linkID="1493327" linkType="Reference"&gt;1493327&lt;/ulink&gt;], [&lt;ulink linkID="1493283" linkType="Reference"&gt;1493283&lt;/ulink&gt;].   In June 2014, post-hoc analysis data from 418 patients were presented at the EULAR 2014 Annual Meeting in Paris, France. At week 24, greater mean changes from baseline in patient-reported outcomes were observed in patients treated with clazakizumab +/- methotrexate compared with those treated with methotrexate alone. A significantly higher proportion of patients treated with clazakizumab had achieved minimal clinically important differences than those treated with methotrexate alone [&lt;ulink linkID="1563875" linkType="Reference"&gt;1563875&lt;/ulink&gt;]. In June 2014, further data were presented at the same meeting. In the clazakizumab + methotrexate arms, favourable numerical changes from baseline in X-ray erosion and modified total sharp score (mTSS) and MRI-assessed pathologies of joint damage were observed compared with methotrexate. At week 24, a numerically higher proportion of patients were X-ray non-progressors for erosion, joint space and mTSS in the clazakizumab + methotrexate arms than those in the methotrexate monotherapy group [&lt;ulink linkID="1565525" linkType="Reference"&gt;1565525&lt;/ulink&gt;]. In June 2014, data were presented at the same meeting. At week 12, a significantly greater proportion of clazakizumab-treated patients achieved ACR 20, 50 and 70 responses (61 to 78.3%, 26.7 to 49.2% and 11.9 to 26.7%, respectively) than those treated with methotrexate alone (39.3, 21.3 and 8.2, respectively); similar effects were seen at week 24. In the clazakizumab arms, higher rates of low disease activity and remission were observed compared with methotrexate alone. Also, reductions in HAQ-DI scores and mean CRP levels were observed with clazakizumab [&lt;ulink linkID="1565564" linkType="Reference"&gt;1565564&lt;/ulink&gt;]. In November 2014, further data from the trial were presented from the 78th ACR Annual Meeting in Boston, MA. Data demonstrated that patients tended to have better patient-reported outcomes and attained rapid onset within 3 months on multiple measures of stringent efficacy [&lt;ulink linkID="1611354" linkType="Reference"&gt;1611354&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2008, a placebo-controlled, randomized, double-blind, phase II trial (&lt;ulink linkID="49677" linkType="Protocol"&gt;NCT00867516&lt;/ulink&gt;; ALD518-CLIN-003) began to assess  three different doses of clazakizumab in RA patients (expected n = 127) who had not had an adequate response to methotrexate. At that time, the trial was estimated to complete in August 2009 [&lt;ulink linkID="1045754" linkType="Reference"&gt;1045754&lt;/ulink&gt;]. In June 2010, clinical data were presented at the Annual Congress of the European League against Rheumatism (EULAR) in Rome, Italy. All three clazakizumab dose groups met the primary endpoint of significant improvements in ACR20 versus placebo at week 12. At week 16, ARC20 was achieved by 75 to 82% of clazakizumab recipients compared with 36% for placebo, ARC50 was achieved by 41 to 50% of clazakizumab recipients compared with 15% for placebo, and ARC70 was achieved by 22 to 43% of clazakizumab recipients compared with 6% for placebo [&lt;ulink linkID="1108272" linkType="Reference"&gt;1108272&lt;/ulink&gt;]. In November 2010, clinical data from the 16-week study were presented at the Annual Meeting of the American College of Rheumatology in Atlanta, GA. At week 16, improvements in physical component summary  scores and mental component summary  scores were observed in all the three dose groups of 80, 160 and 320 mg. Clazakizumab showed  higher mean changes from baseline in bodily pain, general health and social functioning compared to placebo group [&lt;ulink linkID="1159240" linkType="Reference"&gt;1159240&lt;/ulink&gt;]. In May 2011,  further data were presented at the EULAR 2011 in London, UK. In clazakizumab treated groups, SF-6D scores were 3- to 4-fold the minimum important difference (0.041) and the highest SF-6D scores were observed in clazakizumab 320 mg group (0.170), at week 16 [&lt;ulink linkID="1194708" linkType="Reference"&gt;1194708&lt;/ulink&gt;]. In October 2013, safety and efficacy   data were presented at ACR  Annual Meeting in San Diego, CA that clazakizumab  demonstrated consistent safety profile [&lt;ulink linkID="1518323" linkType="Reference"&gt;1518323&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2009, Alder reported clinical data showing that treatment with clazakizumab 80 or 160 mg produced significantly better sustained suppression of CRP levels and faster changes in disease scores, compared with treatment with 4 or 8 mg/kg of  &lt;ulink linkID="6259" linkType="Drug"&gt;tocilizumab&lt;/ulink&gt; and methotrexate     [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Psoriatic arthritis&lt;/subtitle&gt;In January  2012, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="83224" linkType="Protocol"&gt;NCT01490450&lt;/ulink&gt;; IM133-004; 2011-004016-29) was initiated in patients with active psoriatic arthritis who are not responding to NSAID or DMARD therapy (expected n = 150) in Australia, North America, Europe, South Africa and Argentina, to assess the safety and efficacy of clazakizumab. At that time, the study was scheduled to  complete in December 2014 [&lt;ulink linkID="1253802" linkType="Reference"&gt;1253802&lt;/ulink&gt;]. In June 2014, data from the phase IIb study were expected by the end of 2014 [&lt;ulink linkID="1571014" linkType="Reference"&gt;1571014&lt;/ulink&gt;]. In November 2014, clinical data were presented at the 78th ACR Annual Meeting in Boston, MA. ACR 20 response rate, the primary endpoint was met and  was 46.3, 52.4 and 39% at week 16 and 56.1, 57.1 and 39% at week 24 in the clazakizumab 25, 100 and 200 mg groups, respectively compared with placebo (29.3% at week 16 and 34.1% at week 24) [&lt;ulink linkID="1608629" linkType="Reference"&gt;1608629&lt;/ulink&gt;], [&lt;ulink linkID="1612694" linkType="Reference"&gt;1612694&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Crohn's disease&lt;/subtitle&gt;In March 2012, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="85401" linkType="Protocol"&gt;NCT01545050&lt;/ulink&gt;; IM133-005; 2011-004763-72) was planned in patients with Crohn's disease (expected n = 288), to assess the safety and efficacy of clazakizumab. At that time, the study was scheduled to begin in In April of that year, and complete in October 2015 [&lt;ulink linkID="1276534" linkType="Reference"&gt;1276534&lt;/ulink&gt;]. In August 2012, the trial was initiated [&lt;ulink linkID="1318111" linkType="Reference"&gt;1318111&lt;/ulink&gt;]. By June 2013, the trial had been terminated [&lt;ulink linkID="1276534" linkType="Reference"&gt;1276534&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cancer anemia, fatigue, cachexia and oral mucositis&lt;/subtitle&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In September 2009, Alder expected to initiate a phase II/III study in cancer patients during 2010 [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In July 2011, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="79544" linkType="Protocol"&gt;NCT01403064&lt;/ulink&gt;; ALD518-CLIN-009) was initiated in patients with head and neck cancer, receiving concomitant chemotherapy and radiotherapy (expected n = 96) in the US, to assess the safety and efficacy of clazakizumab in treating oral mucositis. The study was expected to be complete by February 2013 [&lt;ulink linkID="1211333" linkType="Reference"&gt;1211333&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2008,  a worldwide, placebo-controlled, randomized, double-blind, phase II trial (&lt;ulink linkID="49689" linkType="Protocol"&gt;NCT00866970&lt;/ulink&gt;; ALD518-CLIN-004) of clazakizumab began in patients with NSCLC-related fatigue and cachexia  (expected n =  124) patients [&lt;ulink linkID="1014302" linkType="Reference"&gt;1014302&lt;/ulink&gt;]. In September 2009, the study was expected to complete in the fourth quarter of 2009 [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;]. In June 2010, results were presented at the 46th ASCO meeting in Chicago, IL. Compared with patients on placebo, those on clazakizumab showed rapid and sustained increases in hemoglobin, hematocrit and mean corpuscular hemoglobin. Clazakizumab treatment also showed a trend towards increased total and appendicular lean body mass and an improvement in fatigue from baseline  [&lt;ulink linkID="1103193" linkType="Reference"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkID="1104799" linkType="Reference"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkID="1105952" linkType="Reference"&gt;1105952&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;By November 2010, a phase I trial to investigate a subcutaneous formulation of the drug was underway. At that time, data were to be presented later that month at the Annual Meeting of the American College of Rheumatology in Atlanta, GA [&lt;ulink linkID="1145643" linkType="Reference"&gt;1145643&lt;/ulink&gt;]; later that month, data were presented at the Annual Meeting. A rapid and sustained reduction in serum C-reactive protein was seen in clazakizumab-treated subjects [&lt;ulink linkID="1159286" linkType="Reference"&gt;1159286&lt;/ulink&gt;]. In May 2011, data from the double-blind, placebo-controlled, randomized, safety, pharmacokinetic and pharmacodynamic, rheumatoid arthritis trial were presented at the EULAR 2011 in London, UK. Healthy male subjects (n = 27) received 50 or 100 mg sc or 100 mg as &amp;gt; 60-min iv infusion of clazakizumab. During the first 12 weeks, clazakizumab reduced the C-reactive protein levels significantly when compared with placebo, and this reduction sustained up to 24 weeks [&lt;ulink linkID="1194706" linkType="Reference"&gt;1194706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2009, clazakizumab had demonstrated a half-life of approximately 30 days [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2008, the drug entered phase I trials for cancer cachexia [&lt;ulink linkID="978332" linkType="Reference"&gt;978332&lt;/ulink&gt;]. In May 2009, positive results from a phase I trial  were presented at the 45th ASCO meeting in Orlando, FL. Patients were assigned to one of three cohorts (n = 3 per cohort), and received clazakizumab at a dose of 80, 160 or 320 mg as a single iv infusion over 1 h.  Clazakizumab was safe and well tolerated, and demonstrated positive activity in all measured areas of efficacy [&lt;ulink linkID="1010001" linkType="Reference"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkID="1014302" linkType="Reference"&gt;1014302&lt;/ulink&gt;]. In September 2009, Alder reported data from this study showing that doses of 80 to 320 mg clazakizumab reduced plasma C-reactive protein (CRP) levels to below 10 mg/l  within 1 week in cancer patients [&lt;ulink linkID="1056787" linkType="Reference"&gt;1056787&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In 2007, the drug entered phase I trials for rheumatoid arthritis [&lt;ulink linkID="978332" linkType="Reference"&gt;978332&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Graft versus host disease&lt;/subtitle&gt;In March 2012, an open-label, phase I/II trial (&lt;ulink url="NCT01530256"&gt;NCT01530256&lt;/ulink&gt;; ALD518-CLIN-010) was initiated in patients with GVHD who have failed to respond to glucocorticosteroids (expected n = 48) in the US, to assess the safety and efficacy of iv clazakizumab. At that time, the study was scheduled to complete in September 2013 [&lt;ulink linkID="1276771" linkType="Reference"&gt;1276771&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In October 2013, preclinical data were presented at the 77th ACR/ARHP Annual Meeting in San Diego CA. When compared with tocilizumab, clazakizumab showed &amp;gt; 44-fold potency in blocking IL-6 induced  TF-1 cell proliferation and &amp;gt; 31-fold potency in blocking IL-6/sIL-6-induced JAK3 expression.  Clazakizumab was superior by 60-fold in dose and 6-fold in potency to tocilizumab in blocking IL-6 induced serum amyloid-A in humanIL-6 receptor knock in mice [&lt;ulink linkID="1493815" linkType="Reference"&gt;1493815&lt;/ulink&gt;], [&lt;ulink linkID="1492929" linkType="Reference"&gt;1492929&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In January 2014, the European Medicines Agency's Pediatric Committee adopted a positive opinion agreeing a pediatric investigation plan for chronic idiopathic arthritis [&lt;ulink linkID="1518625" linkType="Reference"&gt;1518625&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011, Alder Biopharmaceuticals reported that it would receive a milestone payment for initiating a phase IIb study in rheumatoid arthritis for ALD-518  [&lt;ulink linkID="1201269" linkType="Reference"&gt;1201269&lt;/ulink&gt;]. In August 2012, Alder   received a  milestone payment from BMS for the initiation of a phase II clinical trial of ALD-518/BMS-945429 in Crohns disease  [&lt;ulink linkID="1318111" linkType="Reference"&gt;1318111&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In January 2008, it was disclosed that clazakizumab was developed using Alder's proprietary antibody selection technology [&lt;ulink linkID="866877" linkType="Reference"&gt;866877&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><ExpertReview>&lt;para&gt;Brendan J Jenkins, &lt;ulink linkType="Company" linkID="1054873"&gt;Monash Institute of Medical Research&lt;/ulink&gt;, Clayton, Australia&lt;/para&gt;&lt;para&gt;Submission date: 21 March 2011&lt;br/&gt;Publication date: 02 August 2011&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Abstract&lt;/subtitle&gt;ALD-518 is a neutralizing humanized mAb against IL-6, a potent immunomodulatory cytokine that has been implicated in the pathogenesis of various types of inflammatory disease and cancer. &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt; is developing ALD-518 for the potential injectable treatment of cancer-related anemia, fatigue and cachexia, while licensee &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; is developing the mAb for the potential injectable treatment of rheumatoid arthritis. Reported findings from a limited number of phase I and II clinical trials reveal that ALD-518 is generally well tolerated at several doses administered either subcutaneously or intravenously, with no significant safety concerns. Data generated from these trials also suggest that the efficacy of ALD-518 in alleviating the symptoms of rheumatoid arthritis is comparable with that of existing anti-IL-6-based therapies (eg, &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt;). Similarly, preliminary trials suggest that ALD-518 ameliorates fatigue, cachexia and anemia associated with advanced metastatic cancer. At the time of publication, phase III trials of ALD-518 were yet to be initiated. While the trials reported to date support the continued development of ALD-518 for future clinical use, ultimately more in-depth and long-term trials are necessary to determine whether ALD-518 represents a safe and effective therapy against these and other diseases in which IL-6 plays a causal role.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Introduction&lt;/subtitle&gt;The potent immunomodulatory cytokine IL-6 regulates a host of immune-related processes, including the acute-phase response to injury and infection, and the recruitment, differentiation, activation and survival of leukocytes and osteoclasts [&lt;ulink linkType="Reference" linkID="1181912"&gt;1181912&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181914"&gt;1181914&lt;/ulink&gt;]. Collectively, these actions of IL-6 orchestrate aspects of both innate and adaptive immunity that influence the outcome of the inflammatory response. IL-6-mediated events are facilitated by two distinct modes of signaling: 'classical' signaling involving the interaction of IL-6 with its membrane-bound IL-6Ralpha subunit [&lt;ulink linkType="Reference" linkID="1181916"&gt;1181916&lt;/ulink&gt;], and 'trans-signaling' via a naturally occurring soluble IL-6Ralpha that is proteolytically cleaved from the cell surface [&lt;ulink linkType="Reference" linkID="1181917"&gt;1181917&lt;/ulink&gt;]. Considering the somewhat restricted expression of the membrane-bound IL-6Ralpha, primarily on hepatocytes, monocytes/macrophages and certain types of lymphocytes, IL-6 trans-signaling facilitates the actions of IL-6 on a wide range of cells that would otherwise not be responsive to IL-6. Furthermore, IL-6 trans-signaling has been linked to disease pathogenesis [&lt;ulink linkType="Reference" linkID="1181918"&gt;1181918&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181922"&gt;1181922&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181923"&gt;1181923&lt;/ulink&gt;], leading to the notion that the more restricted classical signaling is important for maintaining homeostasis, including that of the immune system. Irrespective of the mode of IL-6 signaling, IL-6 signals are transmitted via gp130, which serves as the common signal-transducing receptor beta subunit for IL-6 and its related cytokines (eg, IL-11, IL-27, leukemia inhibitory factor and oncostatin M). For both modes of signaling, IL-6 engagement of its IL-6Ralpha subunit leads to gp130 homodimerization and activation of several signaling cascades, in particular the JAK-STAT1/3 and the SH2-domain-containing tyrosine phosphatase (SHP2)-dependent MAPK and PI3K pathways [&lt;ulink linkType="Reference" linkID="1181916"&gt;1181916&lt;/ulink&gt;]. Conversely, gp130-mediated upregulation of suppressor of cytokine signaling (SOCS)3 leads to a negative feedback loop via the binding of SOCS3 to gp130, which results in down-modulation of gp130 signaling.&lt;/para&gt;&lt;para&gt;Increased production of IL-6 has been linked to the development of a variety of chronic inflammatory disorders, including rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA), inflammatory bowel disease (in particular, Crohn's disease and ulcerative colitis) as well as colitis-associated colorectal cancer [&lt;ulink linkType="Reference" linkID="1181922"&gt;1181922&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181925"&gt;1181925&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181926"&gt;1181926&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1207357"&gt;1207357&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1207359"&gt;1207359&lt;/ulink&gt;]. Consistent with a central role for IL-6 in promoting the development of chronic inflammatory diseases, over the last decade an impressive body of clinical evidence, especially for RA, has emerged documenting the successful use of antibody-based strategies to therapeutically target IL-6. However, before presenting background information on the efficacy of existing anti-IL-6 therapeutics, it is worth providing a brief historical perspective on other current therapeutic approaches against this disease.&lt;/para&gt;&lt;para&gt;RA has traditionally been treated with NSAIDs, glucocorticoids and disease-modifying anti-rheumatic drugs (DMARDs). The most commonly prescribed and effective DMARD for the treatment of RA is &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (4-amino-N10-methylpteroyl glutamic acid), an analog of folic acid and aminopterin (4-amino-pteroyl glutamic acid). While &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; monotherapy is generally very well tolerated with few adverse effects at the low dose levels administered, a significant proportion of patients fail to display signs of clinical improvement [&lt;ulink linkType="Reference" linkID="949713"&gt;949713&lt;/ulink&gt;]. Because of the inadequate efficacy of &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt;, drugs that block the actions of the potent pro-inflammatory cytokine TNFalpha, in particular the biologic agents &lt;ulink linkType="Drug" linkID="4567"&gt;etanercept&lt;/ulink&gt;, &lt;ulink linkType="Drug" linkID="6850"&gt;infliximab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt;, have been tested for the treatment of RA. Despite initial enthusiasm based on short-term clinical trials that demonstrated reductions in symptoms and joint destruction together with a low incidence of side effects, long-term clinical data revealed that monotherapy with TNFalpha inhibitors resulted in similar response rates to those observed with &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; monotherapy [&lt;ulink linkType="Reference" linkID="949713"&gt;949713&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1097640"&gt;1097640&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1206189"&gt;1206189&lt;/ulink&gt;]. Although the combination of anti-TNFalpha therapy and &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; led to a greater clinical response in more patients with RA, significant numbers of patients still failed to adequately respond to combination therapy [&lt;ulink linkType="Reference" linkID="949713"&gt;949713&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="974877"&gt;974877&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1097640"&gt;1097640&lt;/ulink&gt;]. Perhaps more importantly, these trials demonstrated that anti-TNFalpha therapy is associated with an increased risk of infections [&lt;ulink linkType="Reference" linkID="974877"&gt;974877&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181942"&gt;1181942&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181944"&gt;1181944&lt;/ulink&gt;], and certain types of malignancy [&lt;ulink linkType="Reference" linkID="1181949"&gt;1181949&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;More recently, two new classes of antibodies that target adaptive immune cells have been approved for the treatment of RA. &lt;ulink linkType="Drug" linkID="6736"&gt;Rituximab&lt;/ulink&gt;, a chimeric mouse/human mAb against the B-cell antigen CD20, is designed to deplete CD20+ B-cells [&lt;ulink linkType="Reference" linkID="206647"&gt;206647&lt;/ulink&gt;]. The use of &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; in combination with &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; in patients with RA that have failed to respond to anti-TNFalpha therapies, while still relatively limited, has yielded promising results [&lt;ulink linkType="Reference" linkID="654479"&gt;654479&lt;/ulink&gt;]. However, as with previous therapies for RA, the clinical response of patients to &lt;ulink linkType="Drug" linkID="6736"&gt;rituximab&lt;/ulink&gt; appears variable and it is probably linked to the extent of B-cell depletion in individual patients [&lt;ulink linkType="Reference" linkID="1181952"&gt;1181952&lt;/ulink&gt;]. Considering the association of T-cell-driven immune responses with the etiology of RA, attention has also turned to &lt;ulink linkType="Drug" linkID="2888"&gt;abatacept&lt;/ulink&gt;, a recombinant soluble fusion protein of the extracellular domain of human CTLA4 and the Fc domain of human IgG1. &lt;ulink linkType="Drug" linkID="2888"&gt;Abatacept&lt;/ulink&gt; interferes with T-cell activation by competing with CD28 for binding to CD80 and CD86, an interaction that is required for T-cell activation. However, the clinical benefit of &lt;ulink linkType="Drug" linkID="2888"&gt;abatacept&lt;/ulink&gt; in combination with other DMARDs has been variable, ranging from significant to marginal when compared with placebo controls receiving monotherapy with the partnering therapy [&lt;ulink linkType="Reference" linkID="1014864"&gt;1014864&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181953"&gt;1181953&lt;/ulink&gt;]. Moreover, dual therapy comprising &lt;ulink linkType="Drug" linkID="2888"&gt;abatacept&lt;/ulink&gt; and another biologic DMARD resulted in a greater incidence of serious adverse events, including infections, relative to monotherapy with either biologic agent [&lt;ulink linkType="Reference" linkID="734750"&gt;734750&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The most widely used anti-IL-6 therapeutic for RA is the humanized anti-IL-6Ralpha mAb &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt;, which inhibits binding of IL-6 to the soluble and membrane-bound forms of the IL-6Ralpha [&lt;ulink linkType="Reference" linkID="1073467"&gt;1073467&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1127996"&gt;1127996&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1138162"&gt;1138162&lt;/ulink&gt;], thus blocking both classical and trans-signaling. The potential of targeting IL-6 was highlighted by the observation that treatment with an anti-IL-6Ralpha mAb suppressed the development of joint disease in the collagen-induced arthritis mouse model [&lt;ulink linkType="Reference" linkID="1181955"&gt;1181955&lt;/ulink&gt;]. The subsequent 'humanization' of this approach resulted in the development of &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; and its use in a host of clinical trials, which have demonstrated that &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt;, either as a monotherapy or together with &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt;, is well tolerated at dose levels that provide significant clinical benefits to patients with moderate-to-severe RA [&lt;ulink linkType="Reference" linkID="843928"&gt;843928&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1073467"&gt;1073467&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1177854"&gt;1177854&lt;/ulink&gt;]. In contrast to monotherapy with either &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; or TNFalpha inhibitors, &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; monotherapy yielded significant clinical benefits compared with placebo within 6 months of initiating treatment, and &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; monotherapy was significantly more efficacious at alleviating joint disease than &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; monotherapy [&lt;ulink linkType="Reference" linkID="1181957"&gt;1181957&lt;/ulink&gt;]. While the available clinical data suggest that &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; may provide certain advantages over TNFalpha-based therapies for the treatment of RA, the risk of infections (comparable with anti-TNFalpha treatments) remains with &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; therapy. In addition, a proportion of patients treated with &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; display increases in lipid and cholesterol levels, and, while the mechanistic basis for this remains unknown, importantly, no association between increased risk of cardiovascular disease and &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; therapy has been reported [&lt;ulink linkType="Reference" linkID="1207357"&gt;1207357&lt;/ulink&gt;]. Nevertheless, together with the observation that not all patients with RA respond appropriately to &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; therapy [&lt;ulink linkType="Reference" linkID="734755"&gt;734755&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1177854"&gt;1177854&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181957"&gt;1181957&lt;/ulink&gt;], these findings have paved the way to search for novel anti-IL-6 agents with the potential for enhanced safety and/or efficacy.&lt;/para&gt;&lt;para&gt;Both preclinical and clinical data have demonstrated that in addition to chronic inflammatory diseases, IL-6 is implicated in the pathogenesis of several types of cancer [&lt;ulink linkType="Reference" linkID="1044632"&gt;1044632&lt;/ulink&gt;], including colon [&lt;ulink linkType="Reference" linkID="1181923"&gt;1181923&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182024"&gt;1182024&lt;/ulink&gt;], lung [&lt;ulink linkType="Reference" linkID="1181927"&gt;1181927&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182022"&gt;1182022&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182023"&gt;1182023&lt;/ulink&gt;], and prostate cancers [&lt;ulink linkType="Reference" linkID="1182027"&gt;1182027&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182028"&gt;1182028&lt;/ulink&gt;], multiple myeloma (MM) [&lt;ulink linkType="Reference" linkID="1182025"&gt;1182025&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181931"&gt;1181931&lt;/ulink&gt;], and the non-malignant, lymphoproliferative disorder Castleman's disease [&lt;ulink linkType="Reference" linkID="1181932"&gt;1181932&lt;/ulink&gt;]. With regard to targeting IL-6 as a potential therapeutic approach for cancer, one such agent is &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="26997"&gt;Centocor Ortho Biotech&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1199159"&gt;1199159&lt;/ulink&gt;]), a chimeric mouse/human mAb that binds to and neutralizes human IL-6 with high affinity [&lt;ulink linkType="Reference" linkID="582792"&gt;582792&lt;/ulink&gt;]. &lt;ulink linkType="Drug" linkID="11474"&gt;Siltuximab&lt;/ulink&gt; has displayed promise in preclinical xenograft models of lung cancer [&lt;ulink linkType="Reference" linkID="1182040"&gt;1182040&lt;/ulink&gt;], and in phase I and II clinical trials in patients with MM [&lt;ulink linkType="Reference" linkID="582792"&gt;582792&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1007671"&gt;1007671&lt;/ulink&gt;], prostate [&lt;ulink linkType="Reference" linkID="1110658"&gt;1110658&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182039"&gt;1182039&lt;/ulink&gt;], or renal cell cancer [&lt;ulink linkType="Reference" linkID="1147424"&gt;1147424&lt;/ulink&gt;], and Castleman's disease [&lt;ulink linkType="Reference" linkID="1129391"&gt;1129391&lt;/ulink&gt;]. At the time of publication, a phase III trial (ClinicalTrials.gov identifier: &lt;ulink linkType="Protocol" linkID="73392"&gt;NCT01266811&lt;/ulink&gt;) of &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; or placebo, in combination with the proteasome inhibitor &lt;ulink linkType="Drug" linkID="15954"&gt;bortezomib&lt;/ulink&gt; and the glucocorticosteroid dexamethasone, in patients with MM was planned.&lt;/para&gt;&lt;para&gt;Patients with cancer, in particular those with advanced lung or gastrointestinal cancers, often experience cachexia, a wasting syndrome that is characterized by, but not limited to, loss of body mass, fatigue and muscle atrophy [&lt;ulink linkType="Reference" linkID="1181934"&gt;1181934&lt;/ulink&gt;]. Cachexia accounts for ~ 20% of all cancer-related deaths [&lt;ulink linkType="Reference" linkID="1181935"&gt;1181935&lt;/ulink&gt;], and IL-6 has emerged as a candidate causative factor of this syndrome [&lt;ulink linkType="Reference" linkID="1181936"&gt;1181936&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1181938"&gt;1181938&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182041"&gt;1182041&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182042"&gt;1182042&lt;/ulink&gt;]. In Apc(Min/+) mice, a model of spontaneous intestinal tumorigenesis characterized by the onset of cachexia, in which mice carry a mutation in the APC (adenomatous polyposis coli) tumor suppressor gene, circulating levels of IL-6 are dramatically elevated and the development of intestinal polyps and cachexia is significantly reduced in IL-6 knockout Apc(Min/+) mice [&lt;ulink linkType="Reference" linkID="1181938"&gt;1181938&lt;/ulink&gt;]. Of note, &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; reduced loss of body mass in human tumor xenograft-induced models of cachexia [&lt;ulink linkType="Reference" linkID="581541"&gt;581541&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A novel investigational agent in the field of IL-6-targeted therapeutics is ALD-518, a neutralizing humanized mAb against IL-6, being developed by &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt; for the potential injectable treatment of cancer-related fatigue, cachexia and anemia [&lt;ulink linkType="Reference" linkID="1204727"&gt;1204727&lt;/ulink&gt;]; in addition, licensee &lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt; is developing ALD-518 for the potential injectable treatment of RA [&lt;ulink linkType="Reference" linkID="1056039"&gt;1056039&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, the safety and efficacy of ALD-518, administered as an intravenous infusion, had been evaluated in a phase I trial in patients with advanced cancer [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;], a phase II trial (&lt;ulink linkType="Protocol" linkID="49689"&gt;NCT00866970&lt;/ulink&gt;) in patients with NSCLC-related fatigue and cachexia [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;], and a phase IIa trial (&lt;ulink linkType="Protocol" linkID="49677"&gt;NCT00867516&lt;/ulink&gt;) in patients with active RA [&lt;ulink linkType="Reference" linkID="1145643"&gt;1145643&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159240"&gt;1159240&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194708"&gt;1194708&lt;/ulink&gt;]. The pharmacokinetic and safety profile of an intravenous formulation of ALD-518 was compared with that of a subcutaneous formulation in a phase I trial in healthy volunteers [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;], and a phase IIb trial (&lt;ulink linkType="Protocol" linkID="78148"&gt;NCT01373151&lt;/ulink&gt;) of the subcutaneous formulation of ALD-518 was recently initiated in patients with moderate-to-severe RA.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Synthesis and SAR&lt;/subtitle&gt;ALD-518 is an aglycosylated, asialated, humanized IgG1 mAb that blocks IL-6 activity [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;]. The identification and production of ALD-518 was achieved using proprietary methods developed by &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt;. In particular, &lt;ulink linkType="Company" linkID="1014060"&gt;Alder&lt;/ulink&gt;'s Mab Xpress Antibody Production System allowed the expression and manufacture of ALD-518 using the yeast Pichia pastoris [&lt;ulink linkType="Reference" linkID="1155414"&gt;1155414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1205513"&gt;1205513&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Preclinical development&lt;/subtitle&gt;ALD-518 is reported to bind to IL-6 with high affinity (4 pM), preventing signaling mediated via the IL-6R [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1205513"&gt;1205513&lt;/ulink&gt;]; however, at the time of publication, further data relating to in vitro, in vivo or ex vivo pharmacological studies of ALD-518 were not available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Toxicity&lt;/subtitle&gt;At the time of publication, data from preclinical toxicity studies of ALD-518 were not available.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Metabolism and pharmacokinetics&lt;/subtitle&gt;A phase I, randomized, double-blind, placebo-controlled, 24-week clinical trial compared the single-dose pharmacokinetic profile of intravenous ALD-518 (100 mg) with that of subcutaneous ALD-518 (50 or 100 mg) in healthy volunteers (n = 6 per ALD-518 dose group; n = 3 per corresponding placebo group) [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;]. Assessments were performed on days 1 to 7 and 10, and then at weeks 2, 4, 6, 8 and 12, at which point the study was unblinded and ALD-518-treated volunteers were followed-up until week 24. The t1/2 of ALD-518 was similar across all three active dose groups (mean range: 30.7 to 33.6 days); in contrast, the median Tmax of ALD-518 was ~ 1 week after subcutaneous administration compared with ~ 1 h after intravenous infusion. Subcutaneous administration of ALD-518 resulted in dose-proportional increases in the AUC and Cmax at doses of 50 and 100 mg. Based on an AUC0-inf of 237, 452 and 764 mg.day/ml for the 50 mg subcutaneous, 100 mg subcutaneous and 100 mg intravenous ALD-518 dose groups, respectively, the bioavailability of ALD-518 was ~ 60% for subcutaneous versus intravenous administration [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The pharmacokinetics of single intravenous doses of ALD-518 (80 to 320 mg infusion over 1 h) were explored in a phase I clinical trial in patients (n = 9) with advanced cancer. Plasma ALD-518 exposure increased in a linear, dose-dependent manner and the median t1/2 was 25 days (range: 20 to 32 days) [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Clinical development&lt;/subtitle&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In the phase I, 24-week clinical trial that evaluated single intravenous (100 mg) and subcutaneous (50 or 100 mg) doses of ALD-518 in healthy volunteers, a rapid and sustained reduction in serum levels of C-reactive protein (CRP), an acute-phase response protein that is an established marker of inflammation, was observed in all ALD-518-treated volunteers [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;A phase I, 12-week clinical trial examined the safety and efficacy of a single dose of ALD-518 (80, 160 or 320 mg iv infusion over 1 h) in patients with advanced, metastatic cancer (colorectal, n = 4; cholangiocarcinoma, n = 2; mesothelioma, n = 2; NSCLC, n = 1) [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;]. Among the nine patients enrolled, five completed all follow-up visits and eight were evaluated for efficacy parameters. Pooled data from patients in all three ALD-518 dose groups were analyzed, with median values (and the range of values for each time-point) from day 1 (pre-dose) and at 2, 4 and 12 weeks post-dose being reported. As assessed using the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) questionnaire, ALD-518 reversed fatigue (median FACIT-F score [range]: 21.5 [14.0 to 28.0] on day 1 versus 29.5 [20.0 to 33.5] at week 12; p &amp;lt; 0.05). In addition, ALD-518 was associated with a dramatic reduction in serum CRP levels (range: 17.6 to 131.6 mg/l on day 1 versus 0.2 to 4.5 mg/l at week 12; p &amp;lt; 0.05), and an increase in levels of hemoglobin (range: 11.2 to 14.0 g/l on day 1 versus 12.4 to 15.8 g/l at week 12; p &amp;lt; 0.05) and albumin (range: 33.5 to 39.5 g/l on day 1 versus 38.5 to 46.0 g/dl at week 12; p &amp;lt; 0.05). A trend towards improved hand grip strength was observed, with the improvement being significant at week 2 post-dose (range: 9.7 to 35.4 kg on day 1 versus 10.7 to 36.7 kg at week 2; p &amp;lt; 0.05), but not at week 4 (range: 17.3 to 36.3 kg) or week 12 (range: 19.5 to 35.9 kg). A reduction in platelet counts, the relevance of which relates to the role of IL-6 in promoting platelet production (see [&lt;ulink linkType="Reference" linkID="1211679"&gt;1211679&lt;/ulink&gt;]), was also observed in patients treated with ALD-518 (please see Side effects and contraindications section for further details) [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180234"&gt;1180234&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;Cancer-related anemia, fatigue and cachexia&lt;br/&gt;A phase II, multicenter, randomized, double-blind, placebo-controlled, single-group-assignment, 24-week clinical trial (&lt;ulink linkType="Protocol" linkID="49689"&gt;NCT00866970&lt;/ulink&gt;) assessed the safety and efficacy of ALD-518 (80 [n = 28], 160 [n = 33] or 320 [n = 32] mg iv infusion, once every 8 weeks for 16 weeks) in patients (n = 124) with NSCLC-related fatigue and cachexia. Key inclusion criteria for the study were: a confirmed diagnosis of advanced NSCLC incurable by other treatments including surgery, loss of &gt;/= 5% body mass in the preceding 3 months, serum levels of CRP &gt;/= 10 mg/l, and a life expectancy of &gt;/= 12 weeks. Patients were monitored by follow-up visits at week 20 and 24. Only 29 patients completed the trial, with 52 dying of progressive disease, 5 withdrawing because of adverse events and 38 failing to complete every visit. Accordingly, statistically-valid comparisons were only possible by pooling the data collected up to week 12 of the trial from the remaining patients in all three ALD-518 dose groups, and comparing this with data from the remaining patients in the placebo group [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;From pre-dose on day 1 to week 12, patients who received ALD-518 had a mean loss of lean body mass of 0.19 kg (41.90 +/- 9.35 kg [n = 93] to 41.71 +/- 10.3 kg [n = 35]), compared with a mean loss of lean body mass of 1.50 kg for patients who received placebo (41.58 +/- 10.74 kg [n = 31] to 40.08 +/- 11.00 kg [n = 20]). There were also improvements from pre-dose on day 1 to week 12 in fatigue in ALD-518-treated patients (mean FACIT-F score: 20.5 +/- 9.6 [n = 93] to 23.8 +/- 10.9 [n = 39]) compared with placebo-treated patients (mean FACIT-F score: 21.9 +/- 9.6 [n = 31] to 22.1 +/- 13.2 [n = 21]). Evaluation of the potential benefits of ALD-518 in terms of amelioration of disease symptoms (using the Functional Assessment of Cancer Therapy - Lung questionnaire) demonstrated that relative to placebo, ALD-518 was associated with an improvement, albeit minimal, in the mean lung symptom score from pre-dose day 1 (ALD-518: 13.3 +/- 4.3 [n = 93], placebo: 13.7 +/- 3.4 [n = 31]) to week 12 (ALD-518: 15.6 +/- 5.2 [n = 39], placebo: 15.2 +/- 3.9 [n = 21]) [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;]. A trend toward a reduction from baseline in serum D-dimer concentrations (a measure of thrombosis), was observed in the ALD-518 dose groups compared with the placebo groups. Serum levels of CRP were reduced at all time points measured (2, 4, 8 and 12 weeks post-dose) in all ALD-518 dose groups (p &amp;lt;/= 0.05), except for the 80-mg dose group at week 8, compared with the placebo group [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In addition, patients who received ALD-518 displayed increases in levels of hemoglobin (from 11.5 +/- 2.1 g/dl on day 1 [n = 93] to 13.4 +/- 1.6 g/dl at week 12 [n = 39]; p &amp;lt; 0.0001), hematocrit (37.9 +/- 6.2% to 42.5 +/- 4.7%; p &amp;lt; 0.0002), mean corpuscular hemoglobin (28.4 +/- 2.8 pg to 29.8 +/- 2.8 pg; p &amp;lt; 0.0001) and albumin (37.3 +/- 5.3 g/l to 45.2 +/- 4.5 g/l; p &amp;lt; 0.0001), relative to patients in the placebo group (hemoglobin: 12.2 +/- 1.8 [n = 31] to 12 +/- 2.5 g/dl [n = 31]; hematocrit: 39.0 +/- 5.9 to 39.6 +/- 7.4%; mean corpuscular hemoglobin: 29.0 +/- 2.8 to 27.8 +/- 3.0 pg; and albumin: 37.5 +/- 5.7 to g/l to 37.0 +/- 7.5 g/l) [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;]. These data suggested that ALD-518 may also be effective in treating cancer-related anemia. Similar to the 12-week trial, a decline in platelet counts was observed (further details provided in the Side effects and contraindications section) [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Rheumatoid arthritis&lt;br/&gt;A phase IIa, multicenter, randomized, double-blind, placebo-controlled, parallel-group-assignment, dose-ranging, 16-week clinical trial (&lt;ulink linkType="Protocol" linkID="49677"&gt;NCT00867516&lt;/ulink&gt;) assessed the safety and efficacy of two iv infusions of ALD-518 (80 [n = 32], 160 [n = 34] or 320 mg [n = 28] on day 1 and in week 8) in patients (n = 127) with active RA who had an inadequate response to &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; [&lt;ulink linkType="Reference" linkID="1155414"&gt;1155414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159240"&gt;1159240&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194708"&gt;1194708&lt;/ulink&gt;]. Inclusion criteria included active RA for &gt;/= 16 weeks, serum CRP &gt;/= 10 mg/l and treatment with a stable &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; dose (&gt;/= 10 mg/week) for &gt;/= 3 months. The primary endpoint was the incidence and severity of adverse events and serious adverse events (see Side effects and contraindications section). The secondary endpoint was to evaluate the number of patients achieving a 20, 50 or 70% reduction in the response criteria of the American College of Rheumatology (ACR). The criteria for an ACR20, ACR50 or ACR70 response are the respective reduction (ie, 20, 50 or 70%) in the number of swollen and tender joints, as well as improvement in three of the following: physician global assessment of disease, patient global assessment of disease, patient assessment of pain, CRP or erythrocyte sedimentation rate, and health assessment questionnaire score. At baseline, the mean duration of RA was 6.8 years and the mean Disease Activity Score 28 using CRP (DAS28-CRP) was 6.1, 6.3, 6.2 and 6.2 in the placebo, 80-, 160- and 320-mg ALD-518 groups, respectively [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Data from all 127 patients were available for evaluation [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;]. The primary efficacy endpoint, an ARC20 response at week 12, was achieved by 70.6 to 82.1% of patients across the three ALD-518 dose groups compared with 27.3% of patients in the placebo group (p &amp;lt; 0.05). The week 12 ARC50 and ACR70 response rates ranged from 26.5 to 50.0% and 12.5 to 25.0%, respectively, across the ALD-518 dose groups, compared with 9.1 and 3.0%, respectively, in the placebo group (p &amp;lt; 0.05). At week 16, the ARC20, ACR50 and ACR70 response rate ranged from 75 to 82.1%, 40.6 to 50.0% and 21.9 to 42.9%, respectively, among ALD-518 dose groups, compared with 36.4, 15.2 and 6.1%, respectively, in the placebo group. The mean reduction from baseline at week 16 in DAS28 scores ranged from 2.7 to 3.2 across the three ALD-518 dose groups (no significant difference) compared with 1.1 in the placebo group. DAS28-defined remission (score &amp;lt; 2.6) at week 16 was achieved by 13.8 to 44% of patients in the three ALD-518 dose groups (p &amp;lt; 0.05) compared with 0% of patients in the placebo group. A low disease activity state, defined as DAS28-CRP &amp;lt;/= 3.2, was achieved by 20.7 to 52.0% of patients in the three ALD-518 dose groups (p &amp;lt; 0.05) compared with 3.4% in the placebo group. For nearly all the measures of efficacy, a trend toward greater responses with higher dose levels of ALD-518 was observed [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The impact of ALD-518 on the health-related quality of life of patients was evaluated using the Medical Outcomes Survey Short Form-36 (SF-36) [&lt;ulink linkType="Reference" linkID="1159240"&gt;1159240&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194708"&gt;1194708&lt;/ulink&gt;]. In the placebo, 80-, 160- and 320-mg ALD-518 groups, improvements from baseline in the physical component summary scores were 4.2, 7.1, 6.1 and 8.5, respectively, at week 12, and 4.7, 6.7, 6.6 and 8.3, respectively, at week 16. In the placebo, 80-, 160- and 320-mg ALD-518 groups, improvements from baseline in the mental component summary scores were 1.8, 12.3, 7.6 and 13.5, respectively, at week 12, and 3.8, 10.8, 9.4 and 11.0, respectively, at week 16. The improvement in mental component summary scores at week 16 was greater in the 80- and 320-mg ALD-518 groups (p &amp;lt; 0.05 relative to the placebo group). With regards to individual categories of the SF-36, mean changes from baseline in the social functioning category were greater in all ALD-518 dose groups compared with the placebo (p &amp;lt; 0.05). Significant changes from baseline at week 16 were also observed in some of the other individual categories in some ALD-518 dose groups relative to the placebo group; for example, in the bodily pain (p &amp;lt; 0.05 for 160 mg of ALD-518), general health (p &amp;lt; 0.05 for 80 and 320 mg of ALD-518), vitality (p &amp;lt; 0.05 for 80 mg of ALD-518) and mental health (p &amp;lt; 0.05 for 160 mg of ALD-518) categories [&lt;ulink linkType="Reference" linkID="1159240"&gt;1159240&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194708"&gt;1194708&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;At the time of publication, a subcutaneous formulation of ALD-518 was being evaluated in a phase IIb, multicenter, randomized, double-blind, placebo- and active-controlled, parallel-group-assignment, dose-ranging clinical trial (&lt;ulink linkType="Protocol" linkID="78148"&gt;NCT01373151&lt;/ulink&gt;; IM133-001; 2010-023956-99) that was recruiting patients (expected n = 406) with moderate-to-severe RA who had an inadequate response to &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt;. Patients were to be assigned to one of six ALD-518 groups, which would be compared with a control group receiving &lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt;: arm 1 would receive 200 mg of ALD-518 every 4 weeks from week 25 to 48 plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly from week 1 to 24; arm 2 would receive 200 mg of ALD-518 every 4 weeks plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly, both from week 1 to 48; arm 3 would receive 100 mg of ALD-518 every 4 weeks plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly, both from week 1 to 48; arm 4 would receive 25 mg of ALD-518 every 4 weeks from week 1 to 24 increasing to 200 mg every 4 weeks for week 25 to 48 plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly from week 1 to 48; arm 5 would receive 200 mg of ALD-518 every 4 weeks from week 1 to 48 plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly from week 25 to 48; arm 6 would receive 100 mg of ALD-518 every 4 weeks from week 1 to 48 plus &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly from week 25 to 48; and arm 7 would receive &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt; (15 mg po) weekly plus &lt;ulink linkType="Drug" linkID="14163"&gt;adalimumab&lt;/ulink&gt; (40 mg sc) every 2 weeks, both from weeks 1 to 48. The primary endpoint was to compare the efficacy of ALD-518 with that of placebo on a background of &lt;ulink linkType="Drug" linkID="69847"&gt;methotrexate&lt;/ulink&gt;, as assessed using the ACR20 response criteria at 12 weeks. Secondary endpoints were to assess the efficacy of ALD-518 at 12 weeks by using ACR20, ACR50 and ACR70 response rates, DAS28-CRP, and the clinical and simplified disease activity indexes; to assess the efficacy of ALD-518 at 24 weeks, using the same measures as at 12 weeks but with the addition of outcomes related to remission, physical function and health-related quality of life; to assess radiographic progression of joint damage by MRI and X-ray at 12 and 24 weeks, respectively; and, to assess the safety and tolerability of ALD-518 at 12 and 24 weeks, including immunogenicity rates, by the number of adverse events, serious adverse events, laboratory values, physical exams, vital signs and ECGs. Collection of final data for assessment of the primary endpoint was scheduled for March 2013; completion of the trial was expected in February 2014.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Side effects and contraindications&lt;/subtitle&gt;The phase I, 24-week clinical trial that evaluated single intravenous and subcutaneous doses of ALD-518 in healthy volunteers was completed by all participants [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;]. There were no deaths, serious adverse events or withdrawals from the trial because of adverse events. Adverse events were experienced by 89% of volunteers, and, with the exception of one case of gastroenteritis in the 50-mg ALD-518 group, all were of mild-to-moderate severity. Injection site reactions were reported by 0 of 6 and 1 of 3 volunteers in the intravenous ALD-518 and intravenous placebo groups, respectively, and by 5 of 12 and 1 of 6 volunteers in the subcutaneous ALD-518 and subcutaneous placebo groups, respectively. Apart from one case of moderate erythema and pruritus in the 100-mg subcutaneous ALD-518 group, all injection site reactions were mild. The incidence of grade 1 or 2 elevations in conjugated (ie, excretable) bilirubin levels and neutrophil counts was greater in the ALD-518 dose groups than the placebo groups [&lt;ulink linkType="Reference" linkID="1159286"&gt;1159286&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1194706"&gt;1194706&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase I, 12-week clinical trial of ALD-518 in nine patients with advanced cancer, four patients withdrew because of disease progression: one patient in the 80-mg dose group withdrew after the week 1 visit, one patient in the 160-mg dose group withdrew after the week 8 visit and two patients in the 320-mg dose group withdrew after visits at week 8 and 10, respectively [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;]. Serious adverse events comprised three cases of disease progression and one case of sepsis secondary to a blocked biliary stent. The most common adverse events apart from disease progression were nausea, vomiting, abdominal pain, diarrhea and gastroesophageal reflux disease, which all occurred in &gt;/= 25% of patients. No DLTs, infusion reactions or grade 3 or 4 toxicities were reported. Pooled data from all three ALD-518 dose groups demonstrated that neutrophil and platelet counts declined during the first 4 weeks post-dose, but stabilized from week 4 to week 12. Platelet counts were reduced by ~ 2-fold from pre-dose on day 1 (268 to 362 x 10[9]/l) to week 12 (109 to 203 x 10[9]/l, p &amp;lt; 0.05), suggesting that a single intravenous dose of 80 to 320 mg of ALD-518 was safe and well tolerated [&lt;ulink linkType="Reference" linkID="1010001"&gt;1010001&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1180244"&gt;1180244&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In the phase II, 24-week clinical trial of ALD-518 in patients with NSCLC-related anemia, cachexia and fatigue, no DLTs were identified, and evidence of immunogenicity, infusion reactions or serious infections was not observed [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;]. The 52 deaths that occurred during the trial were all considered to be caused by progression of NSCLC and unrelated to ALD-518. Serious adverse events were reported by 84 patients, but only one, rectal bleeding associated with hemorrhoids, was considered to be related to ALD-518 treatment. Adverse events that led to five patients discontinuing the trial were also not considered to be related to ALD-518. The number of patients who experienced &gt;/= 1 adverse event was 27, 24, 25 and 25 in the placebo, 80-, 160- and 320-mg ALD-518 groups, respectively. The most frequent adverse events, apart from NSCLC progression (57 patients), were all considered to be caused by NSCLC and included dyspnea (25 patients), chest pain (17 patients), fatigue (16 patients) and cough (13 patients). Grade 4 hypercalcemia was experienced by four patients, two in the 160-mg ALD-518 group, and one each in the placebo and the 80-mg ALD-518 group. A grade 4 gamma-glutamyltransferase elevation occurred in one patient in the placebo group and grade 4 hypokalemia was experienced by one patient in the 160-mg ALD-518 group. No treatment-related changes in vital signs or ECGs were observed [&lt;ulink linkType="Reference" linkID="1103193"&gt;1103193&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1104799"&gt;1104799&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;]. From pre-dose on day 1 to week 12, a moderate decline in the mean platelet count was observed in the ALD-518 dose groups (378 +/- 157 x 10[9]/l [n = 93] to 199 +/- 62 x 10[9]/l [n = 39]; p &amp;lt; 0.0001) relative the placebo group (348 +/- 153 x 10[9]/l [n = 31] to 348 +/- 168 x 10[9]/l [n = 21]); however, no cases of grade 4 thrombocytopenia were reported and there was only one case of grade 3 thrombocytopenia, in a patient treated with 160 mg of ALD-518 [&lt;ulink linkType="Reference" linkID="1151558"&gt;1151558&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;The phase II, 16-week clinical trial of ALD-518 in patients with active RA was completed by 116 of the 127 patients enrolled [&lt;ulink linkType="Reference" linkID="1155414"&gt;1155414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;]. Four patients, two each in the 80- and 320-mg dose groups, discontinued ALD-518 treatment because of adverse events; two of these patients, one each in the 80- and 320-mg dose group, had significant increases in liver enzymes that were considered to be serious adverse events. Among the other seven patients who discontinued the trial, one patient each was in the 80-, 160- and 320-mg ALD-518 group and four were in the placebo group; however, the reason for trial discontinuation was not provided [&lt;ulink linkType="Reference" linkID="1155414"&gt;1155414&lt;/ulink&gt;]. Elevated ALT levels (&gt;/= 3-fold the upper limit of normal) occurred in 12, 6 and 29% of patients in the 80-, 160- and 320-mg ALD-518 groups, respectively. An increase from baseline in total cholesterol levels was also observed with a mean increase at week 16 of 1.1 mM in the ALD-518 groups and 0.2 mM in the placebo group. Transient grade 2 neutropenia was reported by five and four patients in the 80- and 160-mg ALD-518 groups, respectively, while transient grade 3 neutropenia occurred in two patients in the 80-mg ALD-518 group. No infusion reactions or serious infections were observed in any treatment group and there was no evidence of immune reactions to ALD-518 [&lt;ulink linkType="Reference" linkID="1155414"&gt;1155414&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1159282"&gt;1159282&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Patent summary&lt;/subtitle&gt;&lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt; first claimed ALD-518 in &lt;ulink linkType="Patent" linkID="PA6492452"&gt;WO-2008144763&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA6492451"&gt;WO-2008144757&lt;/ulink&gt; (filed in May 2007), which describe neutralizing humanized mAbs against IL-6 for the potential treatment of conditions, such as cancer, anemia, cachexia and arthritis. An equivalent of &lt;ulink linkType="Patent" linkID="PA6492451"&gt;WO-2008144757&lt;/ulink&gt; has been granted in the US as &lt;ulink linkType="Patent" linkID="PA3742008"&gt;US-07935340&lt;/ulink&gt; (expiry due in May 2028), but, at the time of publication, European family members (&lt;ulink linkType="Patent" linkID="PA5539032"&gt;EP-02162469&lt;/ulink&gt; and &lt;ulink linkType="Patent" linkID="PA5543791"&gt;EP-02164514&lt;/ulink&gt;) were still pending grant.&lt;/para&gt;&lt;para&gt;Subsequently, in another series of concurrently published applications, &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt; made claims concerning the use of ALD-518 for treating and diagnosing IL-6 associated diseases. These applications include &lt;ulink linkType="Patent" linkID="PA5616923"&gt;WO-2010065079&lt;/ulink&gt; (broad focus on the treatment or diagnosis of IL-6-related disease), &lt;ulink linkType="Patent" linkID="PA5616920"&gt;WO-2010065072&lt;/ulink&gt; (focused on raising albumin levels and/or lowering CRP levels), &lt;ulink linkType="Patent" linkID="PA5616921"&gt;WO-2010065077&lt;/ulink&gt; (focused on thrombosis) and &lt;ulink linkType="Patent" linkID="PA5616922"&gt;WO-2010065078&lt;/ulink&gt; (focused on cachexia, weakness, fatigue and fever), all of which were filed in November 2008. Continuing its trend for filing a number of IL-6 antibody-focused applications at the same time, &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt; made quite similar sounding claims to those published the previous year, in a further four simultaneously published applications. These applications were &lt;ulink linkType="Patent" linkID="PA6463308"&gt;WO-2011066369&lt;/ulink&gt; (focused on cancer and RA), &lt;ulink linkType="Patent" linkID="PA6463309"&gt;WO-2011066371&lt;/ulink&gt; (focused on treating patients with elevated serum CRP and D-dimer levels, reduced serum albumin levels, cachexia and fatigue), &lt;ulink linkType="Patent" linkID="PA6463311"&gt;WO-2011066374&lt;/ulink&gt; (focused on the prevention or treatment of cachexia, weakness, fatigue and fever), and &lt;ulink linkType="Patent" linkID="PA6463312"&gt;WO-2011066378&lt;/ulink&gt; (focused on thrombosis), all filed in November 2009. In these applications ALD-518 is disclosed as being the same as the 'Ab1' entity referred to in the previous two series of patenting. At the time of publication, no direct national or regional equivalent applications for these had been filed.&lt;/para&gt;&lt;para&gt;An intertwined and complex relationship exists between these three patent families. All three patent families appear to be related to a further patent that has been granted in the US as &lt;ulink linkType="Patent" linkID="PA5441927"&gt;US-07906117&lt;/ulink&gt; (expiry due in November 2028), which covers the use of ALD-518 for treating cachexia, weakness, fatigue and fever.&lt;/para&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="15065"&gt;Bristol-Myers Squibb&lt;/ulink&gt;, as a licensee for &lt;ulink linkType="Company" linkID="1014060"&gt;Alder Biopharmaceuticals&lt;/ulink&gt;' IL-6 antibody technology, has worldwide rights for developing ALD-518 for non-cancerous conditions, namely RA and other autoimmune diseases.&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Current opinion&lt;/subtitle&gt;To date, the best example of the progression of an IL-6-based therapeutic from bench-to-bedside is &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt;, which has demonstrated much promise in the treatment and management of several chronic inflammatory diseases, especially RA and JIA. Perhaps the main drawback associated with &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; is the numerous adverse events, including infections, skin rashes and nausea, albeit generally mild-to-moderate [&lt;ulink linkType="Reference" linkID="1207362"&gt;1207362&lt;/ulink&gt;]; however, for the majority of patients who experience a clinical response, the benefit of alleviating the pain and discomfort of RA, outweighs the inconvenience of side effects. Nevertheless, the search continues for superior anti-IL-6-targeted therapies; for example, molecules with a longer half-life that will allow for less frequent dosing, and/or administration of lower dose levels, to ameliorate disease while minimizing the occurrence of side effects. In this respect, &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; and ALD-518 represent two more recently identified antibodies that specifically target and neutralize the activity of IL-6. At the time of publication, more extensive preclinical and clinical data were available for &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt;, which although still in relatively early-stage development, has displayed promise in terms of safety and efficacy, predominantly in a range of tumor-related disease states including prostate, renal cell and lung cancer, MM, Castleman's disease, and also cancer-related cachexia. The relative success of these preclinical studies and early phase clinical trials support the further clinical development and use of &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; in larger trials examining its efficacy in directly ameliorating tumor growth and/or secondary symptoms associated with advanced stage metastatic cancers (eg, cachexia). Because preclinical studies have implicated IL-6 as a driver of both tumor cell growth and cachexia, from a theoretical viewpoint, the blockade of IL-6 with &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt;, or for that matter with ALD-518 or &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt;, might be expected to directly target both the growth of cancer cells and the secondary effects observed in patients with advanced cancer, related to fatigue and loss of lean body mass.&lt;/para&gt;&lt;para&gt;While preliminary evidence is encouraging for ALD-518, the limited preclinical and clinical data that are currently available make it difficult to gauge the future clinical value, competitiveness or marketplace impact of ALD-518. Because IL-6 has been implicated as a causal factor in a spectrum of inflammatory- and cancer-related diseases, it could be some time before a clear picture emerges regarding the safety/efficacy profile of ALD-518 for the treatment/management of each of these disorders. The future release of detailed unpublished and/or published (preferable) preclinical and clinical data for ALD-518, such as those available for &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; and to a lesser extent &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt;, will hopefully facilitate a full interrogation of any advantages ALD-518 may provide over similar anti-IL-6 therapeutics. For example, although it appears from the limited pharmacokinetic data that ALD-518 has a longer half-life (~ 30 days) compared with that of &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; (~ 17 days) [&lt;ulink linkType="Reference" linkID="1110649"&gt;1110649&lt;/ulink&gt;], ultimately side-by-side comparisons in phase II/III trials will be required to ascertain whether one antibody has safety and therapeutic advantages over the other. Regarding this latter point, it should be noted that ALD-518 has yet to enter any phase III trials.&lt;/para&gt;&lt;para&gt;A common issue that appears to be facing ALD-518 and its current competitors is the occurrence of side effects (primarily infections) which, although based on currently available data are minor-to-moderate in severity, nonetheless provide a gap in the market for alternative anti-IL-6 therapeutics. One potential explanation for these side effects may reside with the fact that ALD-518, &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; block both the classical and the trans mode of IL-6 signaling. As discussed in the introduction, emerging evidence supports the notion that classical IL-6 signaling (via the membrane-bound IL-6Ralpha) plays an important role in maintaining immune homeostasis, whereas IL-6 trans-signaling (via the soluble IL-6Ralpha) is implicated in the pathogenesis of inflammatory disorders and cancers. Thus, while targeting both modes of signaling during a particular disease state would ablate disease-associated trans-signaling, the blockade of classical signaling might impair the body's ability to mount an effective immune response, which could account for the increased incidence of opportunistic infections that are a hallmark of currently approved anti-IL-6-based therapies. Considering this, novel biologic agents designed to specifically target and block IL-6 trans-signaling, have recently been described. A fusion protein &lt;ulink linkType="Drug" linkID="57560"&gt;FE-301&lt;/ulink&gt; (&lt;ulink linkType="Company" linkID="1003412"&gt;Conaris Research Institute&lt;/ulink&gt;/&lt;ulink linkType="Company" linkID="29708"&gt;Ferring Pharmaceuticals&lt;/ulink&gt;), which comprises two extracellular gp130 domains fused to the Fc portion of IgG1, suppressed inflammatory arthritis and septic shock in experimentally-induced mouse models [&lt;ulink linkType="Reference" linkID="1181918"&gt;1181918&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1182017"&gt;1182017&lt;/ulink&gt;]. Furthermore, in mouse models of arthritis, experimentally induced by either classical (collagen-induced arthritis) or trans (antigen-induced arthritis) IL-6 signaling, arthritis was only suppressed by mAbs specifically targeted to the type of IL-6 signaling by which the arthritis was induced [&lt;ulink linkType="Reference" linkID="1182019"&gt;1182019&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;From the wealth of preclinical and clinical data generated over the last decade, there is no doubting the value of therapeutically targeting IL-6 for the treatment of certain inflammatory diseases and cancers, either as a monotherapy or in combination with other therapeutics. Because the data available thus far for ALD-518 and &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt; have been generated from the use of either antibody alone, further investigations into the efficacy of each antibody together with other therapeutics will also be required. This will be pertinent for their potential use in the treatment and management of patients with cancer, especially those suffering from advanced cancer-related symptoms, such as cachexia, fatigue and anemia, for which these antibodies are currently being tested, to determine whether their future use should be primarily as adjuvant or non-adjuvant therapy.&lt;/para&gt;&lt;para&gt;Although the available data are encouraging, it is too early to speculate as to whether ALD-518 will provide any advantages over other agents targeted against IL-6 for the treatment of inflammatory conditions or symptoms associated with advanced cancer. Considering that ALD-518, similar to its predecessor's &lt;ulink linkType="Drug" linkID="6259"&gt;tocilizumab&lt;/ulink&gt; and &lt;ulink linkType="Drug" linkID="11474"&gt;siltuximab&lt;/ulink&gt;, represents an antibody-based approach to target 'global' IL-6 signaling, it too might be predicted to possess the disadvantages (eg, adverse effects, such as infections) of targeting 'immuno-protective' classical IL-6 signaling, rather than the more likely pathological trans-signaling. From this point of view, it will be of great interest to observe whether the future development of agents that specifically target IL-6 trans-signaling will provide advantages over current therapies that suppress global IL-6 signaling.&lt;/para&gt;</ExpertReview><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2019-05-14T00:00:00.000Z</StatusDate><Source id="2155021" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="HU">Hungary</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2019-05-14T00:00:00.000Z</StatusDate><Source id="2155021" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3878">Organ transplant rejection</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1987835" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1007640">CSL Behring LLC</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3878">Organ transplant rejection</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1987835" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2019-05-14T00:00:00.000Z</StatusDate><Source id="2155021" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2019-05-14T00:00:00.000Z</StatusDate><Source id="2155021" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2019-05-14T00:00:00.000Z</StatusDate><Source id="2155021" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2018-01-16T00:00:00.000Z</StatusDate><Source id="2049740" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="AT">Austria</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2018-01-16T00:00:00.000Z</StatusDate><Source id="2049740" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="17">Anemia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="84">Crohns disease</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="425">Cachexia</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1123559">Vitaeris Inc</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988272" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="3209">Oral mucositis</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="3">Pipeline Prioritization</DiscontinuedReason><Indication id="829">Fatigue</Indication><StatusDate>2015-03-13T00:00:00.000Z</StatusDate><Source id="1642989" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-11-10T00:00:00.000Z</StatusDate><Source id="1056039" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2012-03-05T00:00:00.000Z</StatusDate><Source id="1276534" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1201269" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-02-20T00:00:00.000Z</StatusDate><Source id="1571082" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-02-20T00:00:00.000Z</StatusDate><Source id="1571082" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1226335" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1226335" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1226335" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1226335" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2011-06-20T00:00:00.000Z</StatusDate><Source id="1226335" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="WO">World</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2009-11-10T00:00:00.000Z</StatusDate><Source id="1056039" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2012-01-20T00:00:00.000Z</StatusDate><Source id="1253802" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2012-08-27T00:00:00.000Z</StatusDate><Source id="1318111" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2005-08-15T00:00:00.000Z</StatusDate><Source id="617781" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="978332" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2007-12-31T00:00:00.000Z</StatusDate><Source id="978332" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="PL">Poland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2009-01-22T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="84">Crohns disease</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3209">Oral mucositis</Indication><StatusDate>2011-07-25T00:00:00.000Z</StatusDate><Source id="1211333" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="NZ">New Zealand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XL">Eastern Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="829">Fatigue</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="17">Anemia</Indication><StatusDate>2010-06-06T00:00:00.000Z</StatusDate><Source id="1103193" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="616">Graft versus host disease</Indication><StatusDate>2012-03-29T00:00:00.000Z</StatusDate><Source id="1276771" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2008-09-30T00:00:00.000Z</StatusDate><Source id="1014302" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2008-10-31T00:00:00.000Z</StatusDate><Source id="1045754" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2014-09-02T00:00:00.000Z</StatusDate><Source id="1590051" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="RU">Russian Federation</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="GE">Georgia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="RS">Serbia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="IT">Italy</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="291">Rheumatoid arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="AR">Argentina</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1781">Psoriatic arthritis</Indication><StatusDate>2016-05-06T00:00:00.000Z</StatusDate><Source id="1759657" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1123559">Vitaeris Inc</Company><Country id="CA">Canada</Country><DevelopmentStatus id="CU" sortOrder="9">Clinical</DevelopmentStatus><Indication id="2989">Kidney transplant rejection</Indication><StatusDate>2017-12-05T00:00:00.000Z</StatusDate><Source id="1988123" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1014060">Alder Biopharmaceuticals Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="425">Cachexia</Indication><StatusDate>2005-08-15T00:00:00.000Z</StatusDate><Source id="617781" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00987"><Name>IL-6 receptor</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1014060">Alder Biopharmaceuticals Inc</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>1</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="1123559">Vitaeris Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>2</CountTotal></Company><Company><Company id="15065">Bristol-Myers Squibb Co</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>1</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="15563">CSL Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>2</CountActive><CountInactive>1</CountInactive><CountTotal>3</CountTotal></Type></CountsByTypes><Deals><Deal id="128547" title="BMS to develop Alder's ALD-518 in non-oncology-related indications worldwide          "/><Deal id="160290" title="Vitaeris to develop Alder's clazakizumab for chronic inflammatory diseases worldwide  "/><Deal id="244372" title="CSL to advance the development of Vitaeris'clazakizumab against solid organ transplant rejection, with an option to acquire Vitaeris   "/></Deals><PatentFamilies><PatentFamily id="2001650" number="WO-2010009391" title="Compositions monovalent for CD28 binding and methods of use"/><PatentFamily id="2476196" number="US-07906117" title="Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever"/><PatentFamily id="2476440" number="WO-2008144757" title="Novel rabbit antibody humanization methods and humanized rabbit antibodies"/><PatentFamily id="2497165" number="US-08404235" title="Antagonists of IL-6 to raise albumin and/or lower CRP"/><PatentFamily id="2506647" number="WO-2010065072" title="Antagonists of IL-6 to raise albumin and/or lower CRP"/><PatentFamily id="2506683" number="WO-2012071554" title="Anti-IL-6 antibodies for the treatment of oral mucositis"/><PatentFamily id="2542637" number="WO-2011066369" title="Antagonists of IL-6 to raise albumin and/or lower CRP"/><PatentFamily id="2798302" number="WO-2014145521" title="Fermentation process for antibody production"/><PatentFamily id="2798532" number="WO-2014145744" title="Antibody purification and purity monitoring"/><PatentFamily id="2799388" number="WO-2014146074" title="Protocol for identifying and isolating antigen-specific B cells and producing antibodies to desired antigens"/><PatentFamily id="2806111" number="US-10202630" title="Temperature shift for high yield expression of polypeptides in yeast and other transformed cells"/><PatentFamily id="2918931" number="WO-2015054293" title="Anti-IL-6 antibodies for the treatment of psoriatic arthritis"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>5</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>7</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Alder Biopharmaceuticals Inc" id="1014060"/><CountAsOwner>11</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>11</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Vitaeris Inc" id="1123559"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Merck &amp; Co Inc" id="18077"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UCB SA" id="20452"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Virginia Commonwealth University" id="20696"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="GlaxoSmithKline plc" id="28355"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>